PDCD1 and neoplasm: Results from preclinical studies support the idea that inhibition of PD-L1 and PD-1 axis in the tumor microenvironment may promote tumor regression, and in clinical trials, various agents targeting PD-1 or PD-L1 have demonstrated robust response rates in a variety of tumor types [10–16].